Health Care • Biotechnology: Pharmaceutical Preparations
$0.59 ▼ -0.02
(-2.54%)
MKT CAP: $84.4M • VOL: 714.3K
52W L $1 52W H $3
RANI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.6M | $1.0M | $0 |
| YoY Revenue Growth % | +58.9% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$38.3M | -$53.3M | -$66.1M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$29.7M | -$30.0M | -$34.0M |
| EBITDA (Normalized) | -$38.2M | -$53.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.7M | -$35.5M | -$51.2M |
| Capital Expenditures (CapEx) | $88.0K | $268.0K | — |
| Free Cash Flow (FCF) | -$18.8M | -$35.8M | -$51.2M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $18.6M | $3.8M | — |
| Total Debt (Short + Long Term) | $0 | $9.6M | — |
| Total Stockholders' Equity | $33.0M | $2.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RANI.